Sempra (SRE) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Nov, 2025Executive summary
Q2 2025 adjusted EPS was $0.89, matching the prior year, while GAAP earnings were $461 million ($0.71/share), down from $713 million ($1.12/share) in Q2 2024; significant capital investments exceeded $5 billion in H1 2025, with a $13 billion capital plan for the year, prioritizing U.S. utilities and grid modernization.
Progress on value creation initiatives included capital recycling, cost reduction, and non-binding LOIs for equity sales in Sempra Infrastructure and Ecogas México, both expected to close in 2026.
Ongoing transition to a more utility-focused business model, with emphasis on Texas growth, regulatory diversity, and simplification through non-core asset sales.
Continued focus on operational efficiency, customer affordability, and risk mitigation, especially in wildfire-prone areas and through cost-saving initiatives.
Achieved operational milestones, including 100% hardening of SDG&E's Tier 3 transmission, 1,000th LNG cargo from Cameron LNG, and major progress on LNG projects.
Financial highlights
Q2 2025 adjusted earnings were $583 million ($0.89/share), up from $567 million ($0.89/share) in Q2 2024; Q2 2025 GAAP EPS was $0.71, down from $1.12; YTD 2025 adjusted EPS was $2.34, up from $2.24 in 2024.
Q2 2025 revenues were $3.0 billion, flat year-over-year; YTD revenues were $6.8 billion, up from $6.7 billion.
Sempra California saw higher regulatory awards and electric transmission margin, offset by lower CPUC base margin and higher net interest expense.
Sempra Texas had higher equity earnings from Oncor and customer growth, offset by higher expenses and lower consumption.
Sempra Infrastructure posted higher revenues from contract modifications and LNG volumes, but was impacted by FX/inflation in Mexico and deferred tax liabilities.
Outlook and guidance
Affirmed full-year 2025 adjusted EPS guidance of $4.30–$4.70 and 2026 guidance of $4.80–$5.30; long-term EPS CAGR guidance of 7%–9% for 2025–2029.
2025 adjusted EPS guidance excludes regulatory disallowances, FX/inflation in Mexico, and derivative/tax impacts.
Expecting higher earnings contribution from regulated utilities post-2026, improving credit and business risk profile.
Oncor's base rate review expected to conclude in Q1 2026, with potential catalysts including improved ROE, incremental CapEx, and new project earnings.
SDG&E and SoCalGas expect continued stable liquidity and performance, with future results dependent on regulatory outcomes.
Latest events from Sempra
- $65B capital plan and record adjusted EPS drive sector-leading growth outlook.SRE
Q4 202526 Feb 2026 - Q2 2024 earnings rose to $713M, with strong Texas/California growth and major projects advancing.SRE
Q2 20242 Feb 2026 - Q3 EPS fell, but guidance and $3B equity plan reaffirmed; Texas and LNG drive growth.SRE
Q3 202416 Jan 2026 - Q1 2025 EPS up, guidance affirmed, and major asset sales and capital investment drive outlook.SRE
Q1 20258 Jan 2026 - 2024 adjusted EPS hit $4.65, with a $56B capital plan and 7–9% EPS growth targeted.SRE
Q4 20247 Jan 2026 - Board refreshment, performance-based pay, and ambitious ESG targets headline the 2025 proxy.SRE
Proxy Filing1 Dec 2025 - Director nominee Jennifer M. Kirk will become CEO of Exubrion Therapeutics in May 2025.SRE
Proxy Filing1 Dec 2025 - Virtual meeting to elect 11 directors, ratify auditor, and approve executive pay.SRE
Proxy Filing1 Dec 2025 - Adjusted EPS up, major asset sale and Texas/LNG growth drive strong long-term outlook.SRE
Q3 20255 Nov 2025